...
首页> 外文期刊>British Journal of Cancer >Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases
【24h】

Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases

机译:晚期乳腺癌对米托蒽醌的反应:与c-erbB-2蛋白和谷胱甘肽S-转移酶的表达相关

获取原文

摘要

Sixty-eight patients with advanced breast cancer were treated with mitoxantrone and clinical responses assessed. Expression of c-erbB-2 protein and cytosolic glutathione S-transferase (GST) isoenzymes pi, alpha and mu by the primary tumours of these patients was determined immunohistochemically, and correlated with treatment response. Tumours overexpressing c-erbB-2 (n = 16, 23%) showed a lower response rate (50% vs 58%) and shorter duration of response to treatment, compared with c-erbB-2 negative tumours. These associations were not statistically significant but survival following start of treatment was significantly shorter in the c-erbB-2 positive group. For each GST isoenzyme, the response rate and duration of response of the group showing enzyme expression did not differ significantly from those with negatively staining tumours. These data do not support a role for expression of GSTs alone in resistance to mitoxantrone monotherapy in advanced breast cancer. The poorer post treatment survival of patients with c-erbB-2 positive tumours suggests they could be selected for more intensive treatment regimens.
机译:用米托蒽醌治疗了68名晚期乳腺癌患者,并评估了临床反应。通过免疫组织化学方法确定了这些患者原发肿瘤中c-erbB-2蛋白和胞质谷胱甘肽S-转移酶(GST)同工酶pi,α和mu的表达,并与治疗反应相关。与c-erbB-2阴性肿瘤相比,过表达c-erbB-2的肿瘤(n = 16、23%)显示出较低的缓解率(50%比58%),并且对治疗的响应时间更短。这些关联在统计学上不显着,但在c-erbB-2阳性组中,开始治疗后的生存期明显缩短。对于每种GST同工酶,显示酶表达的组的响应率和响应持续时间与肿瘤染色阴性的组无显着差异。这些数据不支持在晚期乳腺癌中单独表达GST对米托蒽醌单药耐药。 c-erbB-2阳性肿瘤患者的治疗后生存期较差,这表明他们可以选择进行更深入的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号